<DOC>
	<DOC>NCT02195687</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).</brief_summary>
	<brief_title>BOTOX® in the Treatment of Crow's Feet Lines in China</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate to severe Crow's Feet Lines. Current or previous treatment with botulinum toxin of any serotype for any condition within the last year Diagnosis of myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis Facial laser or light treatment, microdermabrasion or chemical peels within 3 months Radio frequency laser treatments, phototherapy, blepharoplasty, browlift or related procedure, permanent makeup, oral retinoid therapy or treatment with nonpermanent soft tissue fillers within 1 year Any mediumdepth or deep facial peels within 5 years Periorbital surgery, facelift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>